Pluri Inc.

and Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations, (especially in the section titled Outlook ) as well as elsewhere in this Annual Report and include, among other statements, statements regarding the following: the expected development, time-to-market and potential benefits from our products and ventures, based on our cell-based technology platform in regenerative medicine, immunotherapy, food technology, or food tech, agriculture technology ( AgTech ) and our Contract Development and Manufacturing Organization ( CDMO ) business, as well as potentially in other industries and verticals that have a need for our mass scale and cost-effective cell expansion platform; our expectations of market and industry growth; the prospects of entering into additional license agreements, joint ventures, partnerships or other forms of cooperation with other companies, governments institutes, research organizations and medical institutions, and the ability to maintain those agreements, joint ventures, partnerships or other forms of cooperation; our ability to attract clients for our CDMO business; our pre-clinical and clinical study plans, including timing of initiation, expansion, enrollment, results, and conclusion of trials; achieving regulatory approvals; receipt of future funding from the Israel Innovation Authority ( IIA ), the European Union’s Horizon programs, as well as grants from other independent third parties; ii the capabilities of our placenta expanded ( PLX ) cells, including future collaborations to further advance the developme